Protara Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Protara Therapeutics, Inc. (TARA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$32.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$34.92M.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$71.34M, a 664.15% decline year-over-year.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $12.64M.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$3.09M.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$113.14M, a 191.83% decline from fiscal 2024.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $123.21M, a 697.02% increase from fiscal 2023.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $15.46M.
- Protara Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$11.60M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$32.58M 10-Q · filed 2026-08-11 | ||||||
| 2026-03-31 | -$34.92M 10-Q · filed 2026-05-13 | ||||||
| 2025-12-31 | -$113.14M 10-K · filed 2026-03-10 | ||||||
| 2025-09-30 | -$150.25M 10-Q · filed 2025-11-10 | ||||||
| 2025-06-30 | -$131.30M 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | -$71.34M 10-Q · filed 2026-05-13 | ||||||
| 2024-12-31 | $123.21M 10-K · filed 2026-03-10 | ||||||
| 2024-09-30 | $12.17M 10-Q · filed 2025-11-10 | ||||||
| 2024-06-30 | $49.99M 10-Q · filed 2025-08-11 | ||||||
| 2024-03-31 | $12.64M 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | $15.46M 10-K · filed 2025-03-05 | ||||||
| 2023-09-30 | $9.64M 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | $9.85M 10-Q · filed 2024-08-06 | ||||||
| 2023-03-31 | -$3.09M 10-Q · filed 2024-05-02 | ||||||
| 2022-12-31 | -$11.60M 10-K · filed 2024-03-13 | ||||||
| 2022-09-30 | $11.77M 10-Q · filed 2023-11-03 | ||||||
| 2022-06-30 | -$1.91M 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | -$10.29M 10-Q · filed 2023-05-04 | ||||||
| 2021-12-31 | -$132.92M 10-K · filed 2023-03-08 | ||||||
| 2021-09-30 | -$127.91M 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | -$121.81M 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | -$110.40M 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | $168.83M 10-K · filed 2022-03-09 | ||||||
| 2020-09-30 | $165.39M 10-Q · filed 2021-11-04 | $165.39M 10-Q · filed 2020-11-12 | |||||
| 2020-06-30 | $29.46M 10-Q · filed 2021-08-05 | $29.46M 10-Q · filed 2020-07-31 | |||||
| 2020-03-31 | $35.55M 10-Q · filed 2021-05-06 | $35.55M 10-Q · filed 2020-05-13 | |||||
| 2019-12-31 | -$4.99M 10-K · filed 2021-03-11 | ||||||
| 2019-09-30 | -$3.85M 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | -$2.81M 10-Q · filed 2020-07-31 | ||||||
| 2019-03-31 | -$1.43M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |